Adding abiraterone to standard treatment improves prostate cancer survival by 40 percent

Sunday, June 4, 2017 - 16:21 in Health & Medicine

Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 percent, according to the results of one of the largest ever clinical trials for prostate cancer.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net